



Healthcare Weekly News and Deals –April 20th, 2026

1. [White House Issues Executive Order to Accelerate Medical Treatments for Serious Mental Illness, with Focus on Psychedelic Research and Patient Access.](#)

The White House announced an executive order directing federal agencies to accelerate the research, development, and regulatory review of innovative treatments for serious mental illness, with particular emphasis on psychedelic compounds such as ibogaine for treatment-resistant cases. The order instructs the FDA to issue National Priority Vouchers for Breakthrough Therapy-designated psychedelic drugs, facilitates patient access under the Right to Try Act (including Schedule I substances), and allocates at least \$50 million through ARPA-H for state partnerships and clinical trial support. It also calls for enhanced collaboration and data sharing with the VA, plus expedited rescheduling reviews for qualifying substances post-Phase 3. The action aims to address the mental health crisis impacting over 14 million U.S. adults and elevated suicide rates among veterans by promoting treatments offering enduring therapeutic benefits beyond traditional medications. [\(Link\)](#)

2. [McKesson \(NYSE: MCK\) Signs Agreement with Apollo Funds for \\$1.25 Billion Strategic Minority Interest in Medical-Surgical Solutions Business.](#)

McKesson Corporation (MCK) has entered into an agreement with Apollo Funds for a \$1.25 billion investment in convertible preferred equity, representing an approximately 13% minority stake in its Medical-Surgical Solutions (MMS) business at a ~\$13 billion enterprise valuation. McKesson will retain majority ownership, operating control, and financial consolidation of the unit. The transaction represents a key milestone in McKesson's planned separation and future IPO of MMS, which supplies essential products and solutions to non-acute care settings. Apollo's expertise in carve-outs is expected to support MMS as a well-capitalized standalone company. The deal remains subject to regulatory approvals. [\(Link\)](#)

3. [Global Medical Response \(NYSE: GMRS\) Files S-1 Registration Statement in Advance of Planned IPO.](#)

Global Medical Response (GMR Solutions Inc.) has filed an S-1 registration statement with the SEC for an initial public offering of Class A common stock on the NYSE under the symbol GMRS. The company, the largest U.S. provider of emergency medical services (EMS) and integrated alternate-site care, operates air and ground ambulances across approximately 1,400 counties and serves about 5.5 million patients annually with roughly 34,000 employees. For 2025, GMR reported net revenue of approximately \$5.74 billion and Adjusted EBITDA of \$1.19 billion. [\(Link\)](#)

4. [Eli Lilly \(NYSE: LLY\) Acquires Texas ADC Specialist CrossBridge Bio in ~\\$300 Million Deal to Strengthen Oncology Pipeline.](#)

Eli Lilly (LLY) has acquired Houston-based CrossBridge Bio, a preclinical antibody-drug conjugate (ADC) specialist, in a transaction valued at approximately \$300 million (mix of upfront and milestones). CrossBridge's technology, originating from the University of Texas Health Science Center, features advanced linker stability and multi-payload capabilities, with lead TROP2-targeting dual-payload candidate CBB-120 expected to enter the clinic in 2026. The deal further builds on Lilly's recent ADC acquisitions and internal efforts, enhancing its position in next-generation cancer therapies. [\(Link\)](#)

Healthcare Weekly News and Deals – April 20th, 2026

5. UCB to Acquire Neurona Therapeutics for Up to \$1.15 Billion, Advancing Epilepsy Pipeline with Regenerative Cell Therapy.

UCB has agreed to acquire Neurona Therapeutics, gaining its lead asset NRTX-1001, a pluripotent stem cell-derived neuronal cell therapy currently in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy (mTLE). The total transaction value reaches up to \$1.15 billion, including \$650 million upfront and up to \$500 million in potential milestones. The acquisition advances UCB's leadership in epilepsy by introducing regenerative science approaches aimed at restoring neural circuitry and providing durable seizure control. NRTX-1001 has received FDA RMAT and EMA PRIME designations. The deal is expected to close by the end of Q2 2026, subject to antitrust clearance. ([Link](#))

6. Organon (NYSE: OGN) Shares Surge Following Reports of Acquisition Interest from Leading Private Equity Firms CVC Capital Partners and TPG.

Organon (OGN) witnessed a 25% increase in its stock price amid market reports that CVC Capital Partners and TPG are exploring a potential multi-billion dollar acquisition of the company. The interest from these prominent private equity firms highlights the perceived value in Organon's diverse portfolio of women's health products, biosimilars, and established brands. While a formal deal has not been confirmed, the involvement of CVC and TPG suggests a significant investment opportunity in the pharmaceutical space, as financial sponsors look for stable, cash-flow-generative assets. Investors are keeping a close watch on OGN as potential bidding activities could reshape the women's health sector. ([Link](#))

7. Avanos Medical, Inc. (NYSE: AVNS) Agrees to \$1.272 Billion Acquisition by American Industrial Partners to Transition the Company into Private Ownership.

Avanos Medical, Inc. (AVNS) has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) for approximately \$1.272 billion in an all-cash transaction. AIP's investment values Avanos at \$25.00 per share, representing a significant premium for stockholders. The deal will transition Avanos into a private entity, allowing the company to focus on long-term growth and its innovation roadmap without public market pressures. AIP intends to leverage its deep operational expertise to enhance Avanos's competitive position in the medical technology sector. The acquisition is expected to close in the second half of 2026, marking a new chapter for the medtech firm. ([Link](#))

8. Gyde Acquires Benavest, Marking Its Second Deal in Two Weeks as AI-Enabled Health Insurance Brokerage Expands.

Gyde, an AI-powered health insurance brokerage platform that launched in January 2026 with \$60 million in funding, has acquired Benavest, a national agency specializing in consumer health plans including individual ACA, ICHRA, and Medicare products. The deal follows Gyde's recent acquisition of Medicare brokerage Avid Health. Benavest brings scalable distribution infrastructure and leadership expertise, which Gyde plans to support with its AI-driven GydeOS platform. No financial terms were disclosed. ([Link](#))

Healthcare Weekly News and Deals – April 20th, 2026

9. Signant Health, Supported by Financial Sponsors Harvest Partners, Genstar Capital, and Foresite Capital, Enters into a Definitive Agreement to Acquire Ametris.

Signant Health has signed a definitive agreement to acquire Ametris, a global leader in digital health solutions, with the backing of private equity firms Harvest Partners, Genstar Capital, and Foresite Capital. This acquisition integrates Ametris's clinical trial data management and sensor technologies into Signant's evidence-generation platform. The move is a strategic play by the financial sponsors to consolidate the eClinical technology market, creating a more comprehensive suite of tools for pharmaceutical sponsors. By acquiring Ametris, Signant Health aims to enhance its capabilities in capturing high-quality clinical evidence across virtual, hybrid, and traditional trial models globally. ([Link](#))

10. BTX Precision, via Financial Sponsors L Squared Capital Partners and CFT Capital Partners, Completes the Strategic Acquisition of Maitland Engineering.

BTX Precision has acquired Maitland Engineering to expand its precision manufacturing platform, supported by financial sponsors L Squared Capital Partners and CFT Capital Partners. This acquisition follows a series of strategic moves by BTX, including a recent continuation vehicle led by L Squared and backed by HarbourVest Partners. The investment in Maitland Engineering strengthens BTX Precision's capabilities in producing complex, high-tolerance components for the medical and aerospace industries. L Squared Capital Partners continues to drive the platform's buy-and-build strategy, focusing on integrating specialized regional manufacturers to create a dominant, national high-precision engineering entity with significant operational scale. ([Link](#))

11. CPIhealth, Supported by Financial Sponsor Iron Path Capital, Acquires Midwest Interventional Spine Specialists and Serenity Surgical Center.

CPIhealth, a portfolio company of private equity firm Iron Path Capital, has acquired Midwest Interventional Spine Specialists (M.I.S.S.) and Serenity Surgical Center. This acquisition adds two clinical locations and an ambulatory surgery center to CPIhealth's interventional pain management platform, expanding its presence in the Indiana and Illinois markets. Iron Path Capital's investment facilitates the integration of five additional physicians and multiple nurse practitioners into the platform. This deal underscores the firm's strategy of consolidating regional pain management practices to build a multi-state infrastructure capable of delivering advanced, cost-effective interventional spine care through a standardized clinical and administrative model. ([Link](#))

12. Brado AI Strengthens its Conversational Engagement Platform Through the Strategic Acquisition of ProviderIQ from Hatchleaf.

Brado AI has acquired the ProviderIQ asset from Hatchleaf to enhance its precision routing and patient-provider matching capabilities. This acquisition allows Brado AI to integrate clinically informed data and real-world operational workflows into its Conversational Engagement Platform (CEP). By acquiring the technology co-developed with clinicians from Johns Hopkins, Brado AI is investing in more accurate demand-supply alignment for large healthcare systems. The deal reflects Brado AI's commitment to reducing patient leakage and optimizing provider utilization. The investment highlights a growing trend of AI companies acquiring specialized clinical data tools to provide deeper insights and better ROI for health system partners. ([Link](#))

Healthcare Weekly News and Deals – April 20th, 2026

13. D2 Solutions Acquires PromodRx to Expand Patient Access and Engagement Technologies for Pharmaceutical and Medical Device Manufacturers.

D2 Solutions has completed the acquisition of PromodRx, a cloud-based platform designed to accelerate patient access to prescription medications. This strategic investment expands D2 Solutions' service offerings in market access, reimbursement support, and patient engagement. By integrating PromodRx's technology, D2 Solutions strengthens its UltraTouch Verify and Engage platforms, helping pharmaceutical clients navigate complex prior authorization and benefit verification processes. The acquisition is intended to reduce therapy initiation delays and improve patient adherence, positioning D2 Solutions as a more comprehensive commercialization partner in an increasingly complex pricing and policy environment within the life sciences sector. [\(Link\)](#)

14. H2 Health, a Portfolio Company of Grant Avenue Capital, Expands into Arkansas Through the Strategic Acquisition of Advanced Physical Therapy.

H2 Health, backed by private equity firm Grant Avenue Capital, has acquired Advanced Physical Therapy (APT), a practice with six locations in the Little Rock, Arkansas market. This investment marks H2 Health's expansion into a new state, bringing its total footprint to over 300 clinics across 13 states. Grant Avenue Capital continues to provide the financial resources for H2 Health's aggressive buy-and-build strategy in the outpatient rehabilitation sector. The acquisition of APT allows H2 Health to leverage its centralized administrative infrastructure to improve operational efficiencies at the local level while expanding access to high-quality physical and occupational therapy services. [\(Link\)](#)

15. Afterburner Capital and Council Capital Successfully Exit Their Investment in Advanced Care Partners Following an Eight-Year Growth Period.

Private equity firms Afterburner Capital and Council Capital have announced the successful exit of their portfolio company, Advanced Care Partners (ACP). During their eight-year investment period, the sponsors helped ACP scale its pediatric and adult private duty nursing services across Georgia and Florida. The exit represents a significant milestone for Afterburner and Council Capital, who focused on professionalizing ACP's management and clinical infrastructure to drive growth. This transaction highlights the strong investor demand for home-based care platforms that provide high-quality services to medically fragile populations, as financial sponsors seek exits that demonstrate successful clinical and operational scaling in the healthcare services market. [\(Link\)](#)

16. Stellus Rx, a Portfolio Company of WindRose Health Investors, Acquires Tria Health to Create an Integrated Pharmacist-Led Chronic Care Platform.

Stellus Rx, which is backed by WindRose Health Investors, has acquired Tria Health to expand its pharmacist-led pharmacy care management capabilities. This acquisition merges Stellus Rx's dispensing solutions with Tria Health's chronic condition support services for self-insured employers. WindRose Health Investors is supporting this combination to create a differentiated platform that reduces the total cost of care through improved medication adherence and clinical outcomes. The investment underscores WindRose's strategy of backing companies that deliver cost-effective healthcare solutions. The unified entity aims to leverage shared data and clinical expertise to better manage complex patients across the healthcare continuum. [\(Link\)](#)

17. Mobia Medical (MOBI) Files for a \$100 Million Initial Public Offering Led by BofA Securities, J.P. Morgan, and Goldman Sachs to Advance its Vagus Nerve Stimulation Technology.

Mobia Medical (MOBI), a developer of neurostimulation devices for chronic stroke recovery, has filed with the SEC to raise up to \$100 million in an initial public offering. The IPO process is being led by joint bookrunners BofA Securities, J.P. Morgan, and Goldman Sachs, alongside BTIG and Wolfe | Nomura Alliance. The company, which generated \$32 million in revenue in 2025, intends to use the proceeds to expand its commercial organization and fund further R&D for its Vivistim system. This filing signals a major step for the venture-backed company as it transitions into the public markets to capitalize on the \$30 billion stroke recovery sector. [\(Link\)](#)

Venture Deals and Other

1. Avo (AvoMD) Secures \$10 Million Series A Funding Led by Noro-Moseley Partners with Participation from AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, Scrub Capital, Dunamu & Partners, Mirae Asset Capital, and Futureplay.

Avo (formerly AvoMD) has successfully closed a \$10 million Series A funding round to advance its AI-powered clinical decision support platform. The round was led by Noro-Moseley Partners, featuring a broad syndicate of investors including AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, Epsilon Health, and Scrub Capital. International support came from Korean firms Dunamu & Partners, Mirae Asset Capital, and Futureplay. The capital will be utilized to scale Avo's generative AI copilots within major EHR systems, helping clinicians integrate real-time medical knowledge and hospital protocols directly into their digital workflows to improve patient outcomes. [\(Link\)](#)

2. Bain Capital Life Sciences Backs Beeline Medicines with \$300 Million in Capital to Develop Five Clinical Programs Acquired from Bristol Myers Squibb (BMY).

Beeline Medicines has emerged from stealth with a massive \$300 million investment commitment from Bain Capital Life Sciences. The venture-backed biotech is focused on advancing a portfolio of five clinical-stage programs originally discovered by Bristol Myers Squibb (BMY), targeting autoimmune and inflammatory diseases. This strategic investment allows Beeline to accelerate late-stage clinical development for assets like afimedoran, a TLR7/8 inhibitor. Bain Capital's funding provides the necessary runway for Beeline to operate as an agile, clinical-stage entity, leveraging established pharmaceutical intellectual property to address significant unmet needs in the immunology and gastrointestinal sectors. [\(Link\)](#)

3. Pulnovo Medical Announces Oversubscribed \$100 Million Financing Round with Strategic Investment from Medtronic.

Pulnovo Medical, a pioneer in innovative therapies for pulmonary hypertension, closed an oversubscribed \$100 million financing round featuring a strategic investment from Medtronic. The capital will support the advancement of Pulnovo's clinical programs and commercialization efforts for its pulmonary artery denervation technology. This marks a significant vote of confidence from one of the world's leading medtech companies in the growing field of interventional pulmonary hypertension treatments. [\(Link\)](#)

Healthcare Weekly News and Deals – April 20th, 2026

4. Joyful Health Raises \$17 Million in Series A Funding Led by CRV with Support from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures.

Joyful Health, an AI-driven financial infrastructure provider for the healthcare industry, has secured \$17 million in Series A funding. The investment was led by CRV, with participation from XYZ Venture Capital, Designer Fund, Inflect Capital, and Go Global Ventures. The company plans to use this capital to expand its workforce and accelerate the development of its "financial operating system," which helps healthcare providers automate revenue cycle management and recover unpaid insurance claims. The investors highlighted Joyful Health's ability to leverage AI to identify processing breakdowns and prioritize high-value recovery opportunities for resource-constrained medical practices. [\(Link\)](#)

5. Keebler Health Announces \$16 Million Series A Investment Led by Flare Capital Partners and Sands Capital to Expand AI Capabilities for Unstructured Clinical Data.

Keebler Health has closed a \$16 million Series A round led by Flare Capital Partners, with significant participation from Sands Capital. The funding will scale Keebler's LLM-native platform, which is designed to unlock insights from unstructured clinical documentation—such as provider notes and imaging reports—to improve risk adjustment and value-based care accuracy. Investors noted that Keebler's technology addresses a critical gap in the market where 80% of patient data remains underutilized. This capital injection will support team expansion and the deployment of real-time clinical insights aimed at enhancing both financial performance and patient outcomes for healthcare systems. [\(Link\)](#)

6. Worki Secures \$2.75 Million in Pre-Seed Funding Led by Founders Fund and Y Combinator to Scale its Healthcare Recruitment and Workforce Management Platform.

Healthcare staffing startup Worki has raised \$2.75 million in a pre-seed round led by Founders Fund and Y Combinator. The investment targets the growing labor crisis in healthcare by providing a mobile-first platform that simplifies recruitment and scheduling for both providers and facilities. Founders Fund and Y Combinator are backing Worki's mission to reduce industry reliance on expensive third-party staffing agencies through a more streamlined, automated hiring process. The new capital will be used to enhance the platform's AI-driven matching capabilities and expand its reach across North American health systems struggling with nurse and technician shortages. [\(Link\)](#)